Trial Profile
A Study Comparing Erlotinib Versus Gefitinib As The First-Line Treatment For Patients With Brain-Metastases (BM) From Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 16 May 2017 New trial record